TriSalus Life Sciences Exceeds 2025 Revenue Guidance, Narrows Losses, and Reaffirms 2026 Outlook

summarizeSummary

TriSalus Life Sciences announced robust Q4 and full-year 2025 results, exceeding revenue guidance with 53% annual growth and significantly reducing Adjusted EBITDA losses, while reaffirming strong 2026 revenue guidance.

check_boxKey Events

• Exceeded 2025 Revenue Guidance

  Reported full-year 2025 revenue of $45.2 million, a 53% increase year-over-year, surpassing its 50% guidance. Q4 2025 revenue grew 60% year-over-year to $13.2 million.

• Significant Improvement in Adjusted EBITDA

  Adjusted EBITDA loss for Q4 2025 improved to $0.9 million, compared to a $5.7 million loss in Q4 2024. Full-year Adjusted EBITDA loss narrowed to $17.2 million from $30.0 million in 2024.

• Reaffirmed 2026 Revenue Guidance

  The company reaffirmed its 2026 revenue guidance in the range of $60 million to $62 million, indicating continued growth expectations.

• Strengthened Balance Sheet for Growth

  Subsequent to Q4, the company raised $46 million in gross proceeds from a public offering, which will support continued growth and strategic initiatives, following the offering finalized on February 20, 2026.

auto_awesomeAnalysis

TriSalus Life Sciences reported strong financial results for Q4 and full-year 2025, surpassing its revenue guidance and significantly improving its Adjusted EBITDA. The company's continued commercial momentum, driven by the TriNav® product suite, positions it for further growth. The recent $46 million public offering, which was finalized on February 20, 2026, provides substantial capital to accelerate strategic initiatives and expand the PEDD platform, reinforcing the positive outlook for 2026. This report provides a strong operational context for the recent capital raise and insider purchases.